Secondary Schizophrenia (65 page)

MK-801-increased glutamatergic

Psychopharmacol, 2001.

2004.
173
(3–4):242–8.

and serotonergic transmission in

16
(8):557–77.

164. Henry J. A., Jeffreys K. J., Dawling
the medial prefrontal cortex of the
153. Bialer P. A. Designer drugs in the
S. Toxicity and deaths from 3,4-

rat. Neuropsychopharmacology,

general hospital. Psychiatr Clin

methylenedioxymethamphetamine

2007.
32
(10):2087–97.

North Am, 2002.
25
(1):231–
(Ecstasy). Lancet, 1992.

146. Breese G. R., Knapp D. J., Moy
43.

340
(8816):384–7.

S. S. Integrative role for

154. World Health Organization.

165. Schifano F., Oyefeso A., Corkery
serotonergic and glutamatergic

(1996). Amphetamine Like

J.,
et al.
Death rates from ecstasy
receptor mechanisms in the

Stimulants. Report from the

(MDMA, MDA) and polydrug use

action of NMDA antagonists:

WHO meeting on amphetamines,

in England and Wales 1996–2002.

potential relationships to

MDMA and other

Hum Psychopharmacol, 2003.

psychostimulants. Geneva: WHO.

18
(7):519–24.

Organic Syndromes of Schizophrenia – Section 3

166. Schifano F., Corkery J., Deluca P.,
Phetamine). Arch Gen Psychiatry,

(Ed.). Boston: Little, Brown, pp.

et al.
Ecstasy (MDMA, MDA,
1993.
50
(1):75.

410–18.

MDEA, MBDB) consumption,

175. Schuler S. Early recognition and
182. Mathysse S. (1986). Animal

seizures, related offences, prices,
early intervention in

models in psychiatric reasearch.

dosage levels and deaths in the UK

drug-induced psychoses. Neurol

In Progress in Brain Research, vol
(1994–2003). J Psychopharmacol,

Psychiatr Brain Res, 1998.

65
, van Ree J. M. and Mathysse S.

2006.
20
(3):456–63.

5
(4):197–204.

(Eds.). Amsterdam: Elsevier

167. Solowij N., Hall W., Lee N.

176. Liechti M. E., Geyer M. A., Hell
Science, pp. 259–70.

Recreational MDMA use in

D.,
et al.
Effects of MDMA
183. Creese I., Iversen S. D.

Sydney – a profile of ecstasy users
(ecstasy) on prepulse inhibition

Pharmacological and anatomical

and their experiences with the

and habituation of startle in

substrates of amphetamine

drug. Br J Addict, 1992.

humans after pretreatment with

response in rat. Brain Res, 1975.

87
(8):1161–72.

citalopram, haloperidol, or

83
(3):419–36.

168. Topp L., Hando J., Dillon P.,
et al.

ketanserin. Neuropsychophar-

Ecstasy use in Australia: patterns
macology, 2001.
24
(3):240–
184. Breier A., Malhotra A. K., Pinals
of use and associated harm. Drug

52.

D. A.,
et al.
Association of
Alcohol Depend, 1999.

ketamine-induced psychosis with

177. Vollenweider F. X., Remensberger
focal activation of the prefrontal
55
(1–2):105–15.

S., Hell D.,
et al.
Opposite effects
cortex in healthy volunteers. Am J

169. Lieb R., Schuetz C. G., Pfister H.,
of 3,4-methylenedioxy-

Psychiatry, 1997;
154
(6):805–11.

et al.
Mental disorders in ecstasy
methamphetamine (MDMA) on

users: a prospective-longitudinal
sensorimotor gating in rats versus
185. AbiDargham A., Gil R., Krystal
investigation. Drug Alcohol

healthy humans.

J.,
et al.
Increased striatal
Depend, 2002.
68
(2):195–
Psychopharmacology, 1999.

dopamine transmission in

207.

143
(4):365–72.

schizophrenia: confirmation in a

second cohort. Am J Psychiatry,

170. Falck R. S., Carlson R. G., Wang J.

178. Quednow B. B., Kuhn K. U.,

1998.
155
:761–7.

C.,
et al.
Psychiatric disorders
Hoenig K.,
et al.
Prepulse
and their correlates among young

inhibition and habituation of

186. Homayoun H., Moghaddam B.

adult MDMA users in Ohio.

acoustic tartle response in male

Progression of cellular

J Psychoactive Drugs, 2006.

MDMA (‘ecstasy’) users, cannabis

adaptations in medial prefrontal

38
(1):19–29.

users, and healthy controls.

and orbitofrontal cortex in

response to repeated

171. Sumnell H. R., Cole J. C.

Neuropsychopharmacology, 2004.

amphetamine. J Neurosci, 2006;

Self-reported depressive

29
(5):982–90.

26
(31):8025–39.

symptomatology in community

179. Geyer M. A., Markou A. (2002).

samples of polysubstance

The role of preclinical models in
187. Hill K., Mann L., Laws K. R.,
et al.

misusers who report Ecstasy use: a
the development of psychotropic

Hypofrontality in schizophrenia: a
meta-analysis. J Psychopharmacol,
drugs. In Neuropsychophar-

meta-analysis of functional

2005.
19
(1):84–92.

macology: The Fifth Generation of
imaging studies. Acta Psychiat

Scand, 2004.
110
:243–56.

172. Soar K., Turner J. J. D., Parrott A.

Progress. Davis K. L., Charney D.,
C. Psychiatric disorders in Ecstasy
Coyle J. T., and Nemeroff C.

188. Dom G., Sabbe B., Hulstijn W.,
(MDMA) users: a literature

(Eds.). Philadelphia: Lippincott

van den Brink W. Substance use

review focusing on personal

Williams & Wilkins, pp. 445–55.

disorders and the orbitofrontal

predisposition and drug history.

cortex. Br J Psychiat, 2005.

180. O’Neill M. F., Shaw G.

Hum Psychopharmacol, 2001.

187
:209–20.

Comparison of dopamine

16
(8):641–5.

receptor antagonists on

189. Jentsch J. D., Roth R. H. The
173. Landabaso M. A., Iraurgi I.,
hyperlocomotion induced by

neuropsychopharmacology of

Jimenez-Lerma J. M.,
et al.

cocaine, amphetamine, MK-801

phencyclidine: from NMDA

Ecstasy-induced psychotic

and the dopamine D-1 agonist

receptor hypofunction to the

disorder: six-month follow-up

C-APB in mice. Psychophar-

dopamine hypothesis of

study. Eur Addiction Res, 2002.

macology (Berl), 1999.

schizophrenia.

8
(3):133–40.

145
:237–25.

Neuropsychopharmacology, 1999.

20
(3):201–25.

174. Gouzoulis E., Borchardt D.,

181. Russell R. W. (1964).

Hermle L. A case of toxic

Extrapolation from animals

190. Sams-Dodd F. Strategies to

psychosis induced by Eve

to man. In Animal Behavior

optimize the validity of disease

(3,4-Methylene-Dioxyethylam-

and Drug Action. Steinberg H.

models in the drug discovery

Chapter 10 – Psychotomimetic effects of PCP, LSD, and Ecstasy

process. Drug Discov Today, 2006.

at cloned human and rat

of ketamine. Brain Res, 1999.

11
(7–8):355–63.

dopamine D-2 receptors. Eur J

843
(1–2):171–83.

191. Jackson M. E., Homayoun H.,

Pharmacol, 2006.
540
(1–3):53–6.

209. Duncan G. E., Leipzig J. N.,
Moghaddam B. NMDA receptor

200. Svenningsson P., Nishi A., Fisone
Mailman R. B.,
et al.
Differential
hypofunction produces

G.,
et al.
DARPP-32: an integrator
effects of clozapine and

concomitant firing rate

of neurotransmission. Ann Rev

haloperidol on ketamine-induced

potentiation and burst activity

Pharmacol Toxicol, 2004.

brain metabolic activation. Brain
reduction in the prefrontal cortex.

44
:269–96.

Res, 1998.
812
(1–2):65–75.

Proc Natl Acad Sci USA 2004.

201. Svenningsson P., Tzavara E. T.,
210. Duncan G. E., Moy S. S., Knapp
101
(22):8467–72.

Carruthers R.,
et al.
Diverse
D. J.,
et al.
Metabolic mapping of
192. Carpenter W. T., Koenig J. I. The
psychotomimetics act through a

the rat brain after subanesthetic
evolution of drug development in

common signaling pathway.

doses of ketamine: potential

schizophrenia: past issues and

Science, 2003.
302
(5649):1412–15.

relevance to schizophrenia. Brain
future opportunities.

202. Rabiner E. A. Imaging of striatal
Res, 1998.
787
(2):181–90.

Neuropsychopharmacology, 2008.

dopamine release elicited with

211. Littlewood C. L., Jones N., O’Neill
33
:2061–79. [Epub Nov 28, 2007.]

NMDA antagonists: is there

M. J.,
et al.
Mapping the central
193. Agid Y., Buzsaki G., Diamond D.

anything there to be seen?

effects of ketamine in the rat using
M.,
et al.
Viewpoint – How can
J Psychopharmacol, 2007.

pharmacological MRI.

drug discovery for psychiatric

21
(3):253–8.

Psychopharmacology, 2006.

disorders be improved? Nat Rev

203. Davis S. M., Lees K. R., Albers G.

186
(1):64–81.

Drug Discov, 2007.
6
(3):189–201.

W.,
et al.
Selfotel in acute ischemic
212. Wu J. C., Buchsbaum M. S.,

194. Robbins T. W. (2004). Animal
stroke – possible neurotoxic

Potkin S. G.,
et al.
Positron
models of psychosis. In

effects of an NMDA antagonist.

emission tomography study of

Neurobiology of Mental Illness.

Stroke, 2000.
31
(2):347–54.

phencyclidine users. Schizophr

Charney D. S., Nestler E. J. (Eds.).

204. Moghaddam B., Adams B. W.

Res, 1991.
4
(3):415.

New York: Oxford University

Reversal of phencyclidine effects
213. Cochran S. M., Kennedy M.,

Press, pp. 263–86.

by a group II metabotropic

McKerchar C. E.,
et al.
Induction
195. Kapur S., Seeman P. Ketamine has
glutamate receptor agonist in rats.

of metabolic hypofunction and

equal affinity for NMDA receptors
Science, 1998.
281
(5381):1349–52.

neurochemical deficits after

and the high-affinity state of the
205. Hetzler B. E., Wautlet B. S.

chronic intermittent exposure to

dopamine D-2 recep. Biol

Ketamine-induced locomotion in

phencyclidine: differential

Psychiatr, 2001.
49
(11):954–5.

rats in an open-field. Pharmacol

modulation by antipsychotic

196. Seeman P., Schwarz J., Chen J. F.,
Biochem Behav, 1985.
22
(4):
drugs. Neuropsychopharmacology,

et al.
Psychosis pathways converge
653–5.

2003.
28
(2):265–75.

via D2(High) dopamine receptors.

206. Sams-Dodd F. Distinct effects of
214. Wickelgren I. Neurobiology – a
Synapse, 2006.
60
(4):319–46.

d-amphetamine and

new route to treating

197. Kapur S., Seeman P. NMDA

phencyclidine on the social